We provide you with 20 years of free, institutional-grade data for BMRN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BMRN. Explore the full financial landscape of BMRN stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-10-28 | 1048477 | BMRN | 10-Q | Url |
| 2025-08-05 | 1048477 | BMRN | 10-Q | Url |
| 2025-05-02 | 1048477 | BMRN | 10-Q | Url |
| 2025-02-24 | 1048477 | BMRN | 10-K | Url |
| 2024-10-31 | 1048477 | BMRN | 10-Q | Url |
| 2024-08-05 | 1048477 | BMRN | 10-Q | Url |
| 2024-04-26 | 1048477 | BMRN | 10-Q | Url |
| 2024-02-26 | 1048477 | BMRN | 10-K | Url |
| 2023-11-02 | 1048477 | BMRN | 10-Q | Url |
| 2023-08-02 | 1048477 | BMRN | 10-Q | Url |
| 2023-04-28 | 1048477 | BMRN | 10-Q | Url |
| 2023-02-27 | 1048477 | BMRN | 10-K | Url |
| 2022-10-28 | 1048477 | BMRN | 10-Q | Url |
| 2022-08-04 | 1048477 | BMRN | 10-Q | Url |
| 2022-04-29 | 1048477 | BMRN | 10-Q | Url |
| 2022-02-25 | 1048477 | BMRN | 10-K | Url |
| 2021-10-29 | 1048477 | BMRN | 10-Q | Url |
| 2021-07-30 | 1048477 | BMRN | 10-Q | Url |
| 2021-04-30 | 1048477 | BMRN | 10-Q | Url |
| 2021-02-26 | 1048477 | BMRN | 10-K | Url |
| 2020-11-06 | 1048477 | BMRN | 10-Q | Url |
| 2020-08-05 | 1048477 | BMRN | 10-Q | Url |
| 2020-05-01 | 1048477 | BMRN | 10-Q | Url |
| 2020-02-27 | 1048477 | BMRN | 10-K | Url |
| 2019-10-29 | 1048477 | BMRN | 10-Q | Url |
| 2019-08-02 | 1048477 | BMRN | 10-Q | Url |
| 2019-04-29 | 1048477 | BMRN | 10-Q | Url |
| 2019-02-28 | 1048477 | BMRN | 10-K | Url |
| 2018-10-26 | 1048477 | BMRN | 10-Q | Url |
| 2018-08-03 | 1048477 | BMRN | 10-Q | Url |
| 2018-04-27 | 1048477 | BMRN | 10-Q | Url |
| 2018-02-26 | 1048477 | BMRN | 10-K | Url |
| 2017-10-31 | 1048477 | BMRN | 10-Q | Url |
| 2017-08-02 | 1048477 | BMRN | 10-Q | Url |
| 2017-05-04 | 1048477 | BMRN | 10-Q | Url |
| 2017-02-27 | 1048477 | BMRN | 10-K | Url |
| 2016-11-03 | 1048477 | BMRN | 10-Q | Url |
| 2016-08-08 | 1048477 | BMRN | 10-Q | Url |
| 2016-05-02 | 1048477 | BMRN | 10-Q | Url |
| 2016-02-29 | 1048477 | BMRN | 10-K | Url |
| 2015-11-02 | 1048477 | BMRN | 10-Q | Url |
| 2015-08-05 | 1048477 | BMRN | 10-Q | Url |
| 2015-05-05 | 1048477 | BMRN | 10-Q | Url |
| 2015-03-02 | 1048477 | BMRN | 10-K | Url |
| 2014-10-28 | 1048477 | BMRN | 10-Q | Url |
| 2014-07-31 | 1048477 | BMRN | 10-Q | Url |
| 2014-05-02 | 1048477 | BMRN | 10-Q | Url |
| 2014-02-26 | 1048477 | BMRN | 10-K | Url |
| 2013-10-28 | 1048477 | BMRN | 10-Q | Url |
| 2013-07-29 | 1048477 | BMRN | 10-Q | Url |
| 2013-04-29 | 1048477 | BMRN | 10-Q | Url |
| 2013-02-26 | 1048477 | BMRN | 10-K | Url |
| 2012-10-29 | 1048477 | BMRN | 10-Q | Url |
| 2012-08-02 | 1048477 | BMRN | 10-Q | Url |
| 2012-04-30 | 1048477 | BMRN | 10-Q | Url |
| 2012-02-22 | 1048477 | BMRN | 10-K | Url |
| 2011-10-31 | 1048477 | BMRN | 10-Q | Url |
| 2011-08-01 | 1048477 | BMRN | 10-Q | Url |
| 2011-04-29 | 1048477 | BMRN | 10-Q | Url |
| 2011-02-24 | 1048477 | BMRN | 10-K | Url |
| 2010-10-29 | 1048477 | BMRN | 10-Q | Url |
| 2010-08-04 | 1048477 | BMRN | 10-Q | Url |
| 2010-05-03 | 1048477 | BMRN | 10-Q | Url |
| 2010-02-26 | 1048477 | BMRN | 10-K | Url |
| 2009-10-29 | 1048477 | BMRN | 10-Q | Url |
| 2009-07-31 | 1048477 | BMRN | 10-Q | Url |
| 2009-05-01 | 1048477 | BMRN | 10-Q | Url |
| 2009-02-27 | 1048477 | BMRN | 10-K | Url |
| 2008-11-07 | 1048477 | BMRN | 10-Q | Url |
| 2008-08-06 | 1048477 | BMRN | 10-Q | Url |
| 2008-05-01 | 1048477 | BMRN | 10-Q | Url |
| 2008-02-28 | 1048477 | BMRN | 10-K | Url |
| 2007-11-05 | 1048477 | BMRN | 10-Q | Url |
| 2007-08-09 | 1048477 | BMRN | 10-Q | Url |
| 2007-05-03 | 1048477 | BMRN | 10-Q | Url |
| 2007-02-28 | 1048477 | BMRN | 10-K | Url |
BioMarin Pharmaceutical Inc(NASDAQ:BMRN) 
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment o...
Website: http://www.biomarin.com
Founded: 1997
Full Time Employees: 3,001
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about BMRN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.